SERVICES
Great bonds make Great Proteins.
Integrated services to ____ your molecule from gene ________ to potential drug candidate. ______ multiple host systems - _________, yeast and mammalian.

In the trial version of Web2Disk every fifth word is blanked out. To copy this site with all the words, please upgrade to the full version and copy this website again.
Integrated services to ____ your molecule from gene ________ to potential drug candidate. ______ multiple host systems - _________, yeast and mammalian.
Premas has multiple _____ and suites dedicated to ________ and downstream processing technologies, _________ fully disposable single-use bioreactor _______. We are capable of _______ our customers’ demands on ____, flexibility and productivity. Processes ___________ from our PD labs __________ scale up in our _____-_____ GMP compliant facility. We ____ also successfully performed the __________ and registration of several 2__ and 3rd generation processes.
Our 24/7 running ____ of our processes enable __ to design semi-continuous processes, __________ operations and significantly lower ____ processes. We developed different ____________ and processes to offer ___________ advantages to a number __ new molecule formats and _____________ processes. Some of the ________ include a concomitant increase __ productivity as well as __________ purification, along with low ____.
Premas has the ________ to deliver grams to ___ product and drug substance. __ have now for a __________ product line expanded our ________ to 5kg/week delivery schedules.
This allows Premas __ accelerate development of our ________’ product pipeline and enable ________ deliveries for their clinical ______ in various geographies. We ____ been audited by various __________ and regulatory consultants and _______ assurance groups of our _________.
Premas ___________ in developing
___________ proteins for vaccine
development. Such proteins are _____
“difficult to _______ proteins” (DTE-Ps).
___ innovative D-Crypt platform is
optimized for highyield __________ of
DTE-Ps, __________, or in combination.
Through _ partnership with Akers
Biosciences, Premas is leveraging ______ to develop a multicomponent
recombinant protein vaccine _______
COVID-19.